Expression of Concern: HGF and c-Met Interaction Promotes Migration in Human Chondrosarcoma Cells (PLoS ONE (2013) 8: 1 (e53974) DOI: 10.1371/journal.pone.0053974);HGF and c-Met Interaction Promotes Migration in Human Chondrosarcoma Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Tsou, Hsi Kai ^a,b,c   Chen, Hsien Te ^b,d,e   Hung, Ya Huey ^f   Chang, Chia Hao ^g   Li, Te Mao ^d   Fong, Yi Chin ^d,e   Tang, Chih Hsin ^f,h  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b FENG CHIA UNIVERSITY   (Taiwan)

^c JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g Chang Hua Hospital   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

C MET PROTEIN INHIBITOR; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE C DELTA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CARTILAGE; CHONDROSARCOMA; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 84872171706     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0297300     Document Type: Erratum

References (43)

1. Nakamura T, Nawa K, Ichihara A, (1984) Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochemical and biophysical research communications 122: 1450-1459.
2. Luetteke NC, Michalopoulos GK, (1985) Partial purification and characterization of a hepatocyte growth factor produced by rat hepatocellular carcinoma cells. Cancer research 45: 6331-6337.
3. Funakoshi H, Nakamura T, (2003) Hepatocyte growth factor: from diagnosis to clinical applications. Clinica chimica acta; international journal of clinical chemistry 327: 1-23.
4. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, et al. (2005) Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Critical reviews in oncology/hematology 53: 35-69.
5. Martin TA, Jiang WG, (2010) Hepatocyte growth factor and its receptor signalling complex as targets in cancer therapy. Anti-cancer agents in medicinal chemistry 10: 2-6.
6. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR, (1995) Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer research 55: 1129-1138.
7. Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL, (2003) Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97: 1841-1848.
8. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, et al. (2003) Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer research 63: 1101-1105.
9. Maemura M, Iino Y, Yokoe T, Horiguchi J, Takei H, et al. (1998) Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. Cancer letters 126: 215-220.
10. Toi M, Taniguchi T, Ueno T, Asano M, Funata N, et al. (1998) Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 4: 659-664.
11. Terek RM, Schwartz GK, Devaney K, Glantz L, Mak S, et al. (1998) Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res 16: 585-590.
12. Yuan J, Dutton CM, Scully SP, (2005) RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res 23: 1467-1474.
13. Joyce JA, Pollard JW, (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252.
14. Egeblad M, Werb Z, (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
15. Kerkela E, Saarialho-Kere U, (2003) Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 12: 109-125.
16. Tsai YY, Chiang CC, Yeh KT, Lee H, Cheng YW, (2010) Effect of TIMP-1 and MMP in pterygium invasion. Investigative ophthalmology & visual science 51: 3462-3467.
17. Woodhouse EC, Chuaqui RF, Liotta LA, (1997) General mechanisms of metastasis. Cancer 80: 1529-1537.
18. Hou CH, Hsiao YC, Fong YC, Tang CH, (2009) Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13. Bone 44: 233-242.
19. Hou CH, Chiang YC, Fong YC, Tang CH, (2011) WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells. Biochemical pharmacology 81: 1286-1295.
20. Chen HT, Tsou HK, Tsai CH, Kuo CC, Chiang YK, et al. (2010) Thrombin enhanced migration and MMPs expression of human chondrosarcoma cells involves PAR receptor signaling pathway. Journal of cellular physiology 223: 737-745.
21. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G, (2012) Targeting MET in cancer: rationale and progress. Nature reviews Cancer 12: 89-103.
22. Cecchi F, Rabe DC, Bottaro DP, (2010) Targeting the HGF/Met signalling pathway in cancer. European journal of cancer 46: 1260-1270.
23. Scully SP, Berend KR, Toth A, Qi WN, Qi Z, et al. (2000) Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma. Clinical orthopaedics and related research: 291-303.
24. Tang CH, Chen CF, Chen WM, Fong YC, (2011) IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells. The Journal of biological chemistry 286: 11056-11066.
25. Tang CH, Tsai CC, (2012) CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-kappaB signaling pathway. Biochemical pharmacology 83: 335-344.
26. Hsieh MT, Hsieh CL, Lin LW, Wu CR, Huang GS, (2003) Differential gene expression of scopolamine-treated rat hippocampus-application of cDNA microarray technology. Life sciences 73: 1007-1016.
27. Wang YC, Lee PJ, Shih CM, Chen HY, Lee CC, et al. (2003) Damage formation and repair efficiency in the p53 gene of cell lines and blood lymphocytes assayed by multiplex long quantitative polymerase chain reaction. Analytical biochemistry 319: 206-215.
28. Huang HC, Shi GY, Jiang SJ, Shi CS, Wu CM, et al. (2003) Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain. The Journal of biological chemistry 278: 46750-46759.
29. Tseng CP, Huang CL, Huang CH, Cheng JC, Stern A, et al. (2003) Disabled-2 small interfering RNA modulates cellular adhesive function and MAPK activity during megakaryocytic differentiation of K562 cells. FEBS letters 541: 21-27.
30. Mahtouk K, Tjin EP, Spaargaren M, Pals ST, (2010) The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochimica et biophysica acta 1806: 208-219.
31. Bibollet-Bahena O, Almazan G, (2009) IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways. J Neurochem 109: 1440-1451.
32. Horowitz JC, Lee DY, Waghray M, Keshamouni VG, Thomas PE, et al. (2004) Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem 279: 1359-1367.
33. Huang CY, Fong YC, Lee CY, Chen MY, Tsai HC, et al. (2009) CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol 77: 794-803.
34. Moriya C, Jinnin M, Yamane K, Maruo K, Muchemwa FC, et al. (2011) Expression of matrix metalloproteinase-13 is controlled by IL-13 via PI3K/Akt3 and PKC-delta in normal human dermal fibroblasts. The Journal of investigative dermatology 131: 655-661.
35. Chen YJ, Wei YY, Chen HT, Fong YC, Hsu CJ, et al. (2009) Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 221: 98-108.
36. Hahm ER, Cheon G, Lee J, Kim B, Park C, et al. (2002) New and known symmetrical curcumin derivatives inhibit the formation of Fos-Jun-DNA complex. Cancer Lett 184: 89-96.
37. Qin L, Liao L, Redmond A, Young L, Yuan Y, et al. (2008) The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol 28: 5937-5950.
38. Fong YC, Yang WH, Hsu SF, Hsu HC, Tseng KF, et al. (2007) 2-methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. J Orthop Res 25: 1106-1114.
39. Lesko E, Majka M, (2008) The biological role of HGF-MET axis in tumor growth and development of metastasis. Frontiers in bioscience: a journal and virtual library 13: 1271-1280.
40. Scherer RL, McIntyre JO, Matrisian LM, (2008) Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev 27: 679-690.
41. Koh YW, Choi EC, Kang SU, Hwang HS, Lee MH, et al. (2011) Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met. The Journal of nutritional biochemistry 22: 1074-1083.
42. Sato H, Takino T, (2010) Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer science 101: 843-847.
43. Park SK, Hwang YS, Park KK, Park HJ, Seo JY, et al. (2009) Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells. Carcinogenesis 30: 1225-1233.